PREDICTIVE VALUE OF PATIENT-REPORTED OUTCOMES TO MUCOSAL HEALING IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

被引：0
|
作者：
Colombel, J. F. [1 ]
Han, C. [2 ]
Reinisch, W. [3 ]
Feagan, B. [4 ]
Marano, C. [5 ]
Strauss, R. [5 ]
Johanns, J. [5 ]
Zhang, H. [5 ]
Gibson, P. [6 ]
Collins, J. [7 ]
Rutgeerts, P. [8 ]
Sandborn, W. [9 ]
机构：
[1] Ctr Hosp Univ Lille, Lille, France
[2] Janssen Global Serv LLC, Malvern, PA USA
[3] Univ Vienna, Vienna, Austria
[4] Univ Western Ontario, Robarts Res Inst, London, ON, Canada
[5] Janssen R&D LLC, Spring House, PA USA
[6] Alfred Hosp, Melbourne, Vic, Australia
[7] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[8] Univ Hosp Gasthuisberg, Leuven, Belgium
[9] Univ Calif San Diego, La Jolla, CA 92093 USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.239
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI27
引用
收藏
页码：A40 / A40
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetics of Adalimumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
    Awni, Walid M.
    Eckert, Doerthe
    Sharma, Shringi
    Mostafa, Nael M.
    Noertersheuser, Peter A.
    Pradhan, Rajendra S.
    Robinson, Anne
    Sandborn, William
    Hanauer, Stephen B.
    Colombel, Jean-Frederic
    Thakkar, Roopal
    GASTROENTEROLOGY, 2013, 144 (05) : S229 - S229
  • [22] Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis
    Dulai, Parambir S.
    Mosli, Mahmoud
    Khanna, Reena
    Levesque, Barrett G.
    Sandborn, William J.
    Feagan, Brian G.
    PHARMACOTHERAPY, 2015, 35 (04): : 412 - 423
  • [23] Histological remission and mucosal healing in a randomised, placebo-controlled, Phase 2 study of etrasimod in patients with moderately to severely active ulcerative colitis
    Peyrin-Biroulet, L.
    Panes, J.
    Chiorean, M.
    Zhang, J.
    Vermeire, S.
    Jairath, V.
    Yarur, A.
    Cabell, C.
    Naik, S.
    Sandborn, W. J.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S6 - S6
  • [24] HISTOLOGIC REMISSION AND MUCOSAL HEALING IN A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 STUDY OF ETRASIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Peyrin-Biroulet, Laurent
    Panes, Julian
    Chiorean, Michael V.
    Zhang, Jinkun
    Vermeire, Severine
    Jairath, Vipul
    Yarur, Andres J.
    Cabell, Chris
    Naik, Snehal
    Sandborn, William J.
    GASTROENTEROLOGY, 2019, 156 (06) : S217 - S217
  • [25] Early and sustained improvement in patient-reported outcomes and biomarker concentrations with tulisokibart induction in patients with moderately to severely active ulcerative colitis: A post-hoc analysis from ARTEMIS-UC
    Peyrin-Biroulet, L.
    Yen, M.
    Zhou, W.
    Dong, B.
    Danese, S.
    Feagan, B. G.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1997 - i1998
  • [26] Endoscopically measured mucosal healing correlated with response to therapy in moderately active ulcerative colitis
    Rubin, D. T.
    Yacyshyn, B.
    Yeh, C.
    Lichtenstein, G.
    GUT, 2007, 56 : A119 - A119
  • [27] Cost Per Clinical Outcomes With Biologics for the Treatment of Moderately to Severely Active Ulcerative Colitis
    Jansen, Jeroen P.
    Mody, Reema
    Patel, Haridarshan
    Lorenzi, Maria
    Ursan, Iulia
    Alberton, Mark
    GASTROENTEROLOGY, 2015, 148 (04) : S1 - S2
  • [28] Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
    Yasuo Suzuki
    Satoshi Motoya
    Hiroyuki Hanai
    Takayuki Matsumoto
    Toshifumi Hibi
    Anne M. Robinson
    Nael M. Mostafa
    Jingdong Chao
    Vipin Arora
    Anne Camez
    Roopal B. Thakkar
    Mamoru Watanabe
    Journal of Gastroenterology, 2014, 49 : 283 - 294
  • [29] Integrated summary of safety of obefazimod for patients with moderately to severely active ulcerative colitis
    Vermeire, S.
    Peyrin-Biroulet, L.
    Danese, S.
    Dubinsky, M.
    Dulai, P. S.
    Tilg, H.
    Siegmund, B.
    Hisamatsu, T.
    Shan, K.
    Jacobstein, D.
    Cataldi, F.
    Rabbat, C.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1554 - i1555
  • [30] Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
    Suzuki, Yasuo
    Motoya, Satoshi
    Hanai, Hiroyuki
    Matsumoto, Takayuki
    Hibi, Toshifumi
    Robinson, Anne M.
    Mostafa, Nael M.
    Chao, Jingdong
    Arora, Vipin
    Camez, Anne
    Thakkar, Roopal B.
    Watanabe, Mamoru
    JOURNAL OF GASTROENTEROLOGY, 2014, 49 (02) : 283 - 294
12345